A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2016
Price : $35 *
At a glance
- Drugs Resolvine (Primary)
- Indications Retinal disorders
- Focus Adverse reactions; Therapeutic Use
- 30 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 22 May 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 22 May 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.